RE:RE:RE:RE:China deal I am not sure how the IP protection works but one can only assume all the recent collaborations with Chinese companies would not have been finalized if it was nothing in the contracts to protect the IP. I recall seeing some articles about Wuxi having a go at manufacturing ADCs I found it(below)also they seem to have plans setting up sites in the US.
https://www.fiercepharma.com/manufacturing/kind-a-big-deal-delaware-kicks-19m-for-wuxi-to-build-massive-manufacturing-facility
https://www.fiercepharma.com/manufacturing/establishing-a-new-subsidiary-wuxi-bio-steps-up-its-adc-manufacturing-game
Wino115 wrote: My understanding of the PRC market for pharmaceuticals is that you more or less have to partner with a local-based marketing/distribution firm and perhaps manufacturing too. Between the regulatory hassle, distribution complexity and a government trying to spur their domestic industry on, it's way too hard for pharma's to do on their own so they license out the PRC rights. As for how they protect IP, I'm not sure. There may be domestic manufacturing requirements which sort of forces you to play by their rules if you want access to one of the top 5 markets. I'm not sure on biologics.
I know some of the large pharma's have built plants there to supply raw materials for manufacturing and for generics. Some have stayed and some have pulled out. Pfizer sold to WuXi recently. I would think this is the kind of deal they could get for one indication if they wanted it. I'm also not that sure about pricing but have to assume it's on the low side and, oddly enough, they don't have a nationalized health service for free. They do have private health insurance though and employee health insurance.
scarlet1967 wrote: Often we speculate when a deal should be done earlier with less upfront payment, loyalties etc or later on when there has been some results, This company although they are further in process with their trial than THTX decided based on most likely some encouraging results so far to close a deal relatively early only based on interim results from their phase1 trial. In case of THTX if and when their results are also encouraging it does make sense to chase a similar deal overseas and China would be good place imo because they won't have the resources to sell their potential approved drug in North America let alone China also they do need funds. Let's hope on the back of good results they strike a good deal.
qwerty22 wrote: Such a nice deal for them to secure.